Kintegral Advisory LLC Acquires Shares of 11,763 DexCom, Inc. (NASDAQ:DXCM)

Kintegral Advisory LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, HoldingsChannel reports. The institutional investor bought 11,763 shares of the medical device company’s stock, valued at approximately $1,334,000.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its position in DexCom by 0.3% during the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after purchasing an additional 136,282 shares in the last quarter. Capital Research Global Investors raised its holdings in shares of DexCom by 21.4% during the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after buying an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC grew its stake in shares of DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after buying an additional 1,398,136 shares during the last quarter. Capital World Investors increased its holdings in shares of DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after buying an additional 5,256,092 shares in the last quarter. Finally, Artisan Partners Limited Partnership lifted its stake in shares of DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after acquiring an additional 3,672,471 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. UBS Group lowered their target price on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Stifel Nicolaus upped their price objective on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, August 23rd. Piper Sandler reiterated an “overweight” rating and set a $90.00 target price on shares of DexCom in a research report on Monday. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Finally, Baird R W downgraded DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $112.25.

DexCom Trading Down 2.4 %

NASDAQ:DXCM opened at $70.48 on Thursday. The company has a market cap of $28.03 billion, a PE ratio of 45.47, a PEG ratio of 2.18 and a beta of 1.16. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a 50-day moving average of $92.80 and a 200-day moving average of $115.24.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the company earned $0.34 earnings per share. The company’s revenue for the quarter was up 15.3% on a year-over-year basis. As a group, equities research analysts expect that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $119.24, for a total value of $77,744.48. Following the completion of the sale, the executive vice president now directly owns 67,560 shares of the company’s stock, valued at approximately $8,055,854.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $119.24, for a total transaction of $77,744.48. Following the completion of the transaction, the executive vice president now directly owns 67,560 shares of the company’s stock, valued at approximately $8,055,854.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the sale, the director now directly owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Insiders have sold 4,135 shares of company stock valued at $446,797 in the last three months. 0.30% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.